Popular Articles

ACMG Joins Lawsuit Challenging Patents On Breast Cancer Genes
The American College of Medical Genetics (ACMG) has joined the Association for Molecular Pathology, the College of American Pathologists, and the American Society for Clinical Pathology in a lawsuit filed today charging that patents on the human genes associated with breast and ovarian cancer interfere with diagnostic testing, stifle research and limit women"s options regarding their health care. The lawsuit challenges patents on the BRCA1 and BRCA2 genes, which are responsible for most cases of hereditary breast and ovarian cancers. Because these genes are "products of nature," the ACMG believes that granting patents on them is illegal.
drugs without prescription
Healthcare Reform Starts At Home
As healthcare reform becomes an increasing national priority, the American Psychological Association (APA) and YMCA of the USA announced a partnership that provides strategies to help families improve their overall well-being and physical health, and advocates for a comprehensive healthcare system that has a strong approach to chronic disease prevention. The partnership will specifically address the impact individual behaviors such as eating healthy and increasing physical activity can have in reducing risk factors for chronic diseases.
News of the day
÷£400,000 Birthday Boost For Alzheimer's Society
Britannia Building Society wrapped up its best ever charity fundraising year with a ÷£400,000 birthday boost to Alzheimer"s Society.
Medical Devices

Medicare Part D Healthy For Enrollees

Medicare beneficiaries" activities of daily living (ADL) improved in their first year of the Medicare Part D senior prescription drug plan, according to a ground-breaking study presented at the Annual AcademyHealth meetings in Chicago today. In a study of Medicare records, University of Maryland School of Pharmacy researchers found that Part D in 2006 resulted in "small but statistically significant" improvements in the health status of previously uninsured beneficiaries and in their access to medications. Nearly two-thirds of people with no drug coverage in 2005, before the plan, enrolled in Part D in 2006, the most recent year of available files from the Medicaid Current Beneficiary Survey. "It"s a rich of information about beneficiary characteristics, health status, and activity limitations," said study leader, Amy Davidoff, PhD, research assistant professor at the School. "These individuals arguably had the most to gain from the new program, and thus represent an obvious population of policy interest." Previous studies of Part D focused mainly on enrollment patterns, ease of access and beneficiary options. "Much less is known about the impact of Part D on the health and well being of beneficiaries who enrolled. It will be years before definitive answers are available, but it is now possible to assess selected potential short-term health benefits associated with Part D," said Bruce Stuart, PhD., professor, and director of the School"s Peter Lamy Center on Drug Therapy and Aging. The study also revealed that Part D enrollees experienced twice as much improvement, 8 percent, in their financial hardships than non-enrollees, 4 percent. And, non-enrollees were 3 percent less likely to report improved health in 2006 compared to 2005, relative to enrollees. Both groups reported similar counts of ADL limitations in 2005 but they declined for Part D enrollees, and increased for non-enrollees. "Our findings suggest that in its inaugural year, the program was modestly successful in achieving its stated aims," said Stuart. "The program, now in its fourth year, needs further study to determine whether the short-term gains we identified were maintained or improved further." Medicare Part D is a federal program that subsidizes the costs of prescription drugs for Medicare beneficiaries. It is part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). Part D went into effect on January 1, 2006. The team presented two posters this morning at the AcademyHealth meetings.The study was funded by Novartis Parmaceuticals, Corp. University of Maryland Baltimore


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):